Vasorelaxation

Przewaquinone A
Catalog No: CFN92022

Przewaquinone A has antitumor activity.

Syringaresinol
Catalog No: CFN92060

(-)-Syringaresinol may be a potential chemotherapeutic agent for the treatment of cancer; it against H/R-induced cardiomyocyte injury and death, the degradation of HIF-1α through activation of FOXO3 is a potential therapeutic strategy for ischemia-related diseases. Syringaresinol induces vasorelaxation by enhancing NO production in endothelial cells via two distinct mechanisms, phosphatidylinositol 3-kinase/Akt- and PLC/Ca(2+)/CaMKKβ-dependent eNOS phosphorylation and Ca(2+)-dependent eNOS dimerization.

Leachianone G
Catalog No: CFN92343

Leachianone G exhibits significant antioxidant potentials in the ABTS, ONOO(-), and total ROS assays, it also shows inhibitory activities against pancreatic lipase, it may be used as drug candidate to control obesity. Leachianone G shows potent antiviral activity (IC(50) = 1.6 microg/ml). (+/-)Leachianone G 1b, bearing 8-prenyl and 2',4'-dihydoxyl groups, exhibits potent vasorelaxant and neuroprotective effects.

8-Hydroxypinoresinol
Catalog No: CFN92432

8-Hydroxypinoresinol has antioxidant activity,it and phillygenin significantly reduce the cell injury by 3-morpholinosydnonimine (SIN-1), a ONOO− generator, may be useful for the therapeutic or preventive applications in treating ONOO−-related diseases.

Isorhyncophylline
Catalog No: CFN92553

Isorhyncophylline and rhyncophylline can directly inhibit the contractile responses induced by several agonists in small blood vessels of rat, they also can inhibit the hypertensive effect of angiotensin Ⅱ.